Alembic Pharmaceuticals Limited (APLLTD) Price & Analysis

Compare

1 Followers

APLLTD Stock Chart & Stats

Day’s Range― - ―

52-Week Range₹725.60 - ₹1,296.15

Previous CloseN/A

Volume60.71K

Average Volume (3M)5.51K

Market Cap

₹184.03B

Enterprise Value₹194.32B

Total Cash (Recent Filing)₹901.00M

Total Debt (Recent Filing)₹12.57B

Price to Earnings (P/E)30.5

Beta0.91

Next Earnings

Nov 06, 2025

EPS Estimate

9.3

Last Dividend Ex-Date

Jul 29, 2025

Dividend Yield1.17%

Share Statistics

EPS (TTM)7.90

Shares Outstanding196,563,130

10 Day Avg. Volume3,656

30 Day Avg. Volume5,511

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹931.67

Price Target Upside-0.49% Downside

Rating ConsensusHold

Number of Analyst Covering3

Alembic Pharmaceuticals Limited News

Alembic Pharmaceuticals Gains USFDA Approval for Tretinoin Cream

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited has announced that it received...

13d ago

Alembic Pharmaceuticals Hosts 15th AGM Virtually, Engages Stakeholders

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited held its 15th...

23d ago

Alembic Pharmaceuticals Announces New Auditor Appointments

An update from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) is now available. Alembic Pharmaceuticals Limited announced a change...

23d ago

Alembic Pharmaceuticals Announces New Auditor Appointments

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) has issued an announcement. Alembic Pharmaceuticals Limited announced a change in its...

23d ago

Alembic Pharmaceuticals Updates RTA Contact Details

The latest update is out from Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ). Alembic Pharmaceuticals Limited has announced a...

4M ago

Alembic Pharmaceuticals Completes USFDA Inspection Successfully

Alembic Pharmaceuticals Limited ( ($IN:APLLTD) ) just unveiled an update. Alembic Pharmaceuticals Limited announced the successful completion of...

5M ago

APLLTD FAQ

What was Alembic Pharmaceuticals Limited’s price range in the past 12 months?

Alembic Pharmaceuticals Limited lowest stock price was ₹725.60 and its highest was ₹1296.15 in the past 12 months.

What is Alembic Pharmaceuticals Limited’s market cap?

Alembic Pharmaceuticals Limited’s market cap is ₹184.03B.

When is Alembic Pharmaceuticals Limited’s upcoming earnings report date?

Alembic Pharmaceuticals Limited’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Alembic Pharmaceuticals Limited’s earnings last quarter?

Alembic Pharmaceuticals Limited released its earnings results on Aug 05, 2025. The company reported ₹7.9 earnings per share for the quarter, beating the consensus estimate of ₹7.733 by ₹0.167.

Is Alembic Pharmaceuticals Limited overvalued?

According to Wall Street analysts Alembic Pharmaceuticals Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Alembic Pharmaceuticals Limited pay dividends?

Alembic Pharmaceuticals Limited pays a Annually dividend of ₹11 which represents an annual dividend yield of 1.17%. See more information on Alembic Pharmaceuticals Limited dividends here

What is Alembic Pharmaceuticals Limited’s EPS estimate?

Alembic Pharmaceuticals Limited’s EPS estimate is 9.3.

How many shares outstanding does Alembic Pharmaceuticals Limited have?

Alembic Pharmaceuticals Limited has 196,563,130 shares outstanding.

What happened to Alembic Pharmaceuticals Limited’s price movement after its last earnings report?

Alembic Pharmaceuticals Limited reported an EPS of ₹7.9 in its last earnings report, beating expectations of ₹7.733. Following the earnings report the stock price went down -2.104%.

Which hedge fund is a major shareholder of Alembic Pharmaceuticals Limited?

Currently, no hedge funds are holding shares in IN:APLLTD

Company Description

Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited (APLLTD) is a leading pharmaceutical company headquartered in India, renowned for its expertise in the research, development, manufacturing, and marketing of pharmaceutical products. The company operates in the generic pharmaceuticals sector, providing a wide range of formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments including cardiology, neurology, diabetes, gastroenterology, and more. APLLTD's core services include the development of high-quality medicines that comply with stringent regulatory standards, catering to both domestic and international markets.

Alembic Pharmaceuticals Limited (APLLTD) Earnings & Revenues

Historic Earnings Reports

APLLTD Stock 12 Month Forecast

Average Price Target

₹931.67

▼(-0.49% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"734":"₹734","1203":"₹1,203","851.25":"₹851.3","968.5":"₹968.5","1085.75":"₹1,085.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":950,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹950.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":931.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹931.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":900,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹900.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[734,851.25,968.5,1085.75,1203],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,958.05,957.4307692307692,956.8115384615385,956.1923076923076,955.5730769230769,954.9538461538461,954.3346153846154,953.7153846153846,953.0961538461538,952.4769230769231,951.8576923076923,951.2384615384615,950.6192307692307,{"y":950,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,958.05,956.0207692307691,953.9915384615384,951.9623076923076,949.9330769230769,947.9038461538461,945.8746153846154,943.8453846153845,941.8161538461538,939.786923076923,937.7576923076923,935.7284615384615,933.6992307692308,{"y":931.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,958.05,953.5846153846153,949.1192307692307,944.6538461538461,940.1884615384615,935.7230769230769,931.2576923076923,926.7923076923076,922.3269230769231,917.8615384615384,913.3961538461539,908.9307692307692,904.4653846153847,{"y":900,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1202.28,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1057.93,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1177.4,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1116.38,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1090.32,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1036.86,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":910.02,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":735.65,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":887.71,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":866.8,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":866.8,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1003.48,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":958.05,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >